Stablepharma Limited

Stablepharma Limited is an innovative biopharmaceutical company that aims to revolutionize vaccine storage with its novel technology, StablevaX™. The company's primary goal is to provide fridge-free vaccines, reduce vaccine wastage, and ultimately save lives. Founded in 2012, Stablepharma is dedicated to improving health outcomes for individuals at risk of vaccine-preventable diseases, particularly children and adults. The company's flagship product, SPVX02, is the world's first fridge-free vaccine for Tetanus and Diphtheria. StablevaX is a game-changing technology that offers an extended shelf-life, reduces CO2 footprint, and eliminates the need for refrigeration during vaccine storage and distribution. According to the WHO, approximately 50% of all vaccines manufactured are wasted due to cold chain failures, making Stablepharma's mission critical in addressing this issue. The company's recent £231.97K Equity Crowdfunding investment from Crowdcube on 29 September 2023 underscores investor confidence in Stablepharma's innovative approach to vaccine development and storage. Stablepharma's focus on Biotechnology, Health Care, and Pharmaceutical industries positions it at the forefront of pioneering solutions in global healthcare. With its headquarters in the United Kingdom, the company is well positioned to drive impactful change in the vaccine landscape, benefiting individuals worldwide.